SCLC: is it time for novel therapies?
The search for effective therapeutic targets in small cell lung cancer (SCLC) continues and a number of options have been identified. In the meantime the results of CASPIAN… read more.
The search for effective therapeutic targets in small cell lung cancer (SCLC) continues and a number of options have been identified. In the meantime the results of CASPIAN… read more.
Oligorecurrent and oligoprogressive NSCLC represent a treatment challenge. A case example of synchronous oligometastatic disease provided the framework for expert discussion…….. Written by Christine Clark.
Advances in the use of immunotherapy in thoracic malignancies continued in 2019 with the publication of the results of a number of landmark trials. This has prompted some… read more.
Three expert clinicians, Dr Marina Garassino, Dr Sanjay Popat and Professor Tony Mok presented and discussed cases that illustrated important aspects of the management of ALK-positive NSCLC …… … read more.
The final analyses of two key trials – Checkmate 227, part 1 and FLAURA should help to position nivolumab + ipilimumab combination treatment and to reinforce osimertinib as… read more.
For the second time this year, LungCancer.Med headed to Barcelona for the Annual European Society for Medical Oncology (ESMO) meeting. Written by Christine Clark
Developing CAR-T cells that are effective in solid tumours is challenging but experience in Hodgkin Lymphoma could pave the way for CAR-T cells in lung cancer. Bi-specific T-cell… read more.
Tumours use a variety of mechanisms to escape the host immune system and overcoming these to increase response rates and improve quality of life are key goals. Manipulation… read more.
Targeted treatments for mutation-driven non-small cell lung cancer have advanced considerably but many questions remain about how to use these drugs to the best advantage and how to… read more.
Immunotherapy has been hailed as a “game changer” in the treatment of lung cancer. As experience and understanding grows, optimal ways of delivering this type of treatment are… read more.
Immunotherapy now has an established place in treatment of non-small cell lung cancer but many questions remain such as the role of tumour mutational burden as a biomarker… read more.
“The genome can be thought of as the hardware driving a cell whereas the epigenome is more like the software – it is dynamic and erasable”, said Professor Ari… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.